Nephrology

Phase 3 data show a significant clinical profile associated with durable reductions in IgA nephropathy biomarkers among patients treated with Nefecon.

In their latest column, Kim Zuber, PA-C, and Jane Davis, DNP, break down the concept of "sick day rules" and what this means for providers caring for those with kidney disease.

An analysis of real-world data provides an overview of the effects of GLP-1 receptor agonist and SGLT2 inhibitor use among adults with type 1 diabetes.

Using NHANES data, along with deidentified data from the Optum database, investigators estimate the prevalence of albuminuria testing among people with hypertension or diabetes as well as how the presence or lack of testing might influence prescription of CKD therapies.

A randomized trial of patients with kidney failure undergoing hemodialysis is underlining the importance of physical activity among this patient population.

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

However, the presence of diabetic retinopathy was observed to have no significant impact on physical health and quality of life compared to subjects without retinopathy.

Diabetic retinopathy and microalbuminuria were associated with a significantly higher risk of hemodialysis induction in individuals with T2D.

Research presented at ADA 2023 suggests early glycemic screening in high-risk children may predict future diabetes-related complications, including retinopathy and nephropathy.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.

Gerald B. Appel, MD, discusses the changing treatment landscape of IgAN.

Anuja Java, MD, discusses the role of complement inhibitors in transplant patients with C3G.

In the phase 2b ORIGIN trial, atacicept resulted in a statistically significant reduction in mean proteinuria compared to baseline at week 24.

Carla M. Nester, MD, MSA, FASN discusses recent clinical trials on complement inhibitors for C3G.

Carla M. Nester, MD, MSA, FASN discusses the current therapeutic area for C3G and what is on the horizon.

Anuja Java, MD, discusses barriers to perform kidney biopsies to diagnose immune mediated kidney diseases in community settings.

Sanjeev Sethi, MD, discusses clues in the pathology of kidney biopsies that could lead to a C3G diagnosis.

A panel of glomerular disease specialists discuss the importance of building centers of excellence with expertise on the pathology of C3G.

Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in C3G.

Carla M. Nester, MD, MSA, FASN, discusses the approach to diagnostic testing in pediatric patients suspected of C3G.

Anuja Java, MD, discusses the diagnostic tests that could lead to a diagnosis of C3G.

Sanjeev Sethi, MD, and Gerald B. Appel, MD, discuss how the kidney biopsy can guide treatment and prognosis in IgAN.

Sanjeev Sethi, MD, discusses the role of the electro microscopy in IgAN.

A prospective study on patients with DR and CKD found no significant effect on renal function shortly after performing fluorescein angiography.

Logistic regression analysis indicated that higher stages of urine albumin creatine ratio were significantly associated with diabetic retinopathy in patients with T2D and diabetic nephropathy.

Sanjeev Sethi, MD, discusses the role of the diagnostic kidney biopsy in IgAN.

Anuja Java, MD, discusses the differential diagnosis of C3G.

Data from patients with eGFR of 20 mL/min/1.73m2 or less from the ADVOCATE trial provide new insight into the effects of avacopan use in patients with lower baseline eGFRs.

Anuja Java, MD; Carla M. Nester, MD, MSA, FASN; and Gerald B. Appel, MD, discuss the consequences of a missed or late diagnosis of C3G.

Anuja Java, MD, and Gerald B. Appel, MD, discuss the challenges of managing C3G in their patients.